Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine
Status:
Completed
Trial end date:
2022-02-18
Target enrollment:
Participant gender:
Summary
Patients will be enrolled in one of the two groups using a computer-generated random number
table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will
receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of
dexmedetomidine (total 1.5 mL).